Innovative Medical Tech Avedro’s focus on proprietary corneal cross-linking technology and minimally invasive ophthalmic procedures highlights opportunities for medical device suppliers and healthcare providers seeking cutting-edge refractive and corneal treatments.

Recent Acquisition Move Following its acquisition by Glaukos for 450 million dollars, Avedro is positioned within a broader ophthalmic portfolio, offering potential cross-promotional or collaborative opportunities with other companies targeting corneal and refractive therapies.

Expanding Market Presence Having gone public in early 2019 and with ongoing investments, Avedro is likely seeking growth capital, partners, or distribution channels to expand its reach, especially in outpatient and specialist clinics focused on corneal disorders.

Limited Revenue, High Potential Despite current revenue under 1 million dollars, Avedro's significant funding and technological platform suggest strong growth prospects, making it a promising target for vendors offering complementary ophthalmic solutions and capital equipment.

Strategic Growth Opportunities With a relatively small employee base and high specialization, Avedro may be open to partnerships, joint ventures, or supply chain collaborations to accelerate market penetration for its cross-linking platforms and proprietary formulations.